211 related articles for article (PubMed ID: 36092250)
1. Generation of GLA-knockout human embryonic stem cell lines to model peripheral neuropathy in Fabry disease.
Kaneski CR; Hanover JA; Schueler Hoffman UH
Mol Genet Metab Rep; 2022 Dec; 33():100914. PubMed ID: 36092250
[TBL] [Abstract][Full Text] [Related]
2. Generation of an
Kaneski CR; Hanover JA; Schueler Hoffman UH
Mol Genet Metab Rep; 2022 Jun; 31():100871. PubMed ID: 35782611
[TBL] [Abstract][Full Text] [Related]
3. Generation of
Song HY; Chien CS; Yarmishyn AA; Chou SJ; Yang YP; Wang ML; Wang CY; Leu HB; Yu WC; Chang YL; Chiou SH
Cells; 2019 Apr; 8(4):. PubMed ID: 30965672
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9-based GLA knockout to generate the female Fabry disease human induced pluripotent stem cell line MHHi001-A-15.
Juchem M; Lehmann N; Behrens YL; Bär C; Thum T; Hoepfner J
Stem Cell Res; 2024 Jun; 79():103478. PubMed ID: 38905814
[TBL] [Abstract][Full Text] [Related]
5. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells.
Do HS; Park SW; Im I; Seo D; Yoo HW; Go H; Kim YH; Koh GY; Lee BH; Han YM
EBioMedicine; 2020 Feb; 52():102633. PubMed ID: 31981984
[TBL] [Abstract][Full Text] [Related]
6. Generation of Fabry cardiomyopathy model for drug screening using induced pluripotent stem cell-derived cardiomyocytes from a female Fabry patient.
Kuramoto Y; Naito AT; Tojo H; Sakai T; Ito M; Shibamoto M; Nakagawa A; Higo T; Okada K; Yamaguchi T; Lee JK; Miyagawa S; Sawa Y; Sakata Y; Komuro I
J Mol Cell Cardiol; 2018 Aug; 121():256-265. PubMed ID: 30048710
[TBL] [Abstract][Full Text] [Related]
7. Using CRISPR/Cas9-Mediated GLA Gene Knockout as an In Vitro Drug Screening Model for Fabry Disease.
Song HY; Chiang HC; Tseng WL; Wu P; Chien CS; Leu HB; Yang YP; Wang ML; Jong YJ; Chen CH; Yu WC; Chiou SH
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27983599
[TBL] [Abstract][Full Text] [Related]
8. Generation of a GLA knock-out human-induced pluripotent stem cell line, KSBCi002-A-1, using CRISPR/Cas9.
Kim YK; Yu JH; Min SH; Park SW
Stem Cell Res; 2020 Jan; 42():101676. PubMed ID: 31841972
[TBL] [Abstract][Full Text] [Related]
9. GLA-modified RNA treatment lowers GB3 levels in iPSC-derived cardiomyocytes from Fabry-affected individuals.
Ter Huurne M; Parker BL; Liu NQ; Qian EL; Vivien C; Karavendzas K; Mills RJ; Saville JT; Abu-Bonsrah D; Wise AF; Hudson JE; Talbot AS; Finn PF; Martini PGV; Fuller M; Ricardo SD; Watt KI; Nicholls KM; Porrello ER; Elliott DA
Am J Hum Genet; 2023 Sep; 110(9):1600-1605. PubMed ID: 37607539
[TBL] [Abstract][Full Text] [Related]
10. Molecular Pathogenesis of Central and Peripheral Nervous System Complications in Anderson-Fabry Disease.
Tuttolomondo A; Baglio I; Riolo R; Todaro F; Parrinello G; Miceli S; Simonetta I
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203231
[TBL] [Abstract][Full Text] [Related]
11. Proteomic analysis unveils Gb3-independent alterations and mitochondrial dysfunction in a gla
Elsaid HOA; Rivedal M; Skandalou E; Svarstad E; Tøndel C; Birkeland E; Eikrem Ø; Babickova J; Marti HP; Furriol J
J Transl Med; 2023 Sep; 21(1):591. PubMed ID: 37670295
[TBL] [Abstract][Full Text] [Related]
12. Human kidney organoids reveal the role of glutathione in Fabry disease.
Kim JW; Kim HW; Nam SA; Lee JY; Cho HJ; Kim TM; Kim YK
Exp Mol Med; 2021 Oct; 53(10):1580-1591. PubMed ID: 34654880
[TBL] [Abstract][Full Text] [Related]
13. Endothelial Cell Dysfunction and Hypoxia as Potential Mediators of Pain in Fabry Disease: A Human-Murine Translational Approach.
Klug K; Spitzel M; Hans C; Klein A; Schottmann NM; Erbacher C; Üçeyler N
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895103
[TBL] [Abstract][Full Text] [Related]
14. Characterization of small fiber pathology in a mouse model of Fabry disease.
Hofmann L; Hose D; Grießhammer A; Blum R; Döring F; Dib-Hajj S; Waxman S; Sommer C; Wischmeyer E; Üçeyler N
Elife; 2018 Oct; 7():. PubMed ID: 30328411
[TBL] [Abstract][Full Text] [Related]
15. Dysregulation of Immune Response Mediators and Pain-Related Ion Channels Is Associated with Pain-like Behavior in the GLA KO Mouse Model of Fabry Disease.
Spitzel M; Wagner E; Breyer M; Henniger D; Bayin M; Hofmann L; Mauceri D; Sommer C; Üçeyler N
Cells; 2022 May; 11(11):. PubMed ID: 35681422
[TBL] [Abstract][Full Text] [Related]
16. Dissociation of globotriaosylceramide and impaired endothelial function in α-galactosidase-A deficient EA.hy926 cells.
Kaissarian N; Kang J; Shu L; Ferraz MJ; Aerts JM; Shayman JA
Mol Genet Metab; 2018 Dec; 125(4):338-344. PubMed ID: 30413389
[TBL] [Abstract][Full Text] [Related]
17. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types.
Welford RWD; Mühlemann A; Garzotti M; Rickert V; Groenen PMA; Morand O; Üçeyler N; Probst MR
Hum Mol Genet; 2018 Oct; 27(19):3392-3403. PubMed ID: 29982630
[TBL] [Abstract][Full Text] [Related]
18. Characterization of cellular phenotypes in neurons derived from induced pluripotent stem cells of male patients with Fabry disease.
Miyajima T; Saito R; Yanagisawa H; Igarashi M; Wu C; Iwamoto T; Eto Y
J Inherit Metab Dis; 2023 Jan; 46(1):143-152. PubMed ID: 36220782
[TBL] [Abstract][Full Text] [Related]
19. AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction.
Yasuda M; Huston MW; Pagant S; Gan L; St Martin S; Sproul S; Richards D; Ballaron S; Hettini K; Ledeboer A; Falese L; Cao L; Lu Y; Holmes MC; Meyer K; Desnick RJ; Wechsler T
Mol Ther Methods Clin Dev; 2020 Sep; 18():607-619. PubMed ID: 32775495
[TBL] [Abstract][Full Text] [Related]
20. Generation of a CRISPR/Cas9-corrected-hiPSC line (DDLABi001-A) from Fabry disease (FD)-derived iPSCs having α-galactosidase (GLA) gene mutation (c.803_806del).
Choi JB; Seo D; Do HS; Han YM
Stem Cell Res; 2023 Feb; 66():103001. PubMed ID: 36516658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]